Premium
Fluorine‐19 NMR imaging of glucose metabolism
Author(s) -
Nakada Tsutomu,
Kwee Ingrid L.,
Card Peter J.,
Matwiyoff Nicholas A.,
Griffey Beatrice V.,
Griffey Richard H.
Publication year - 1988
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.1910060309
Subject(s) - aldose reductase , metabolite , chemistry , sorbitol , glycolysis , fluorine 19 nmr , metabolism , carbohydrate metabolism , aldose reductase inhibitor , nuclear magnetic resonance spectroscopy , biochemistry , nuclear magnetic resonance , enzyme , stereochemistry , physics
Metabolic imaging reflecting glucose metabolism in the glycolytic and aldose reductase sorbitol (ARS) pathways was performed noninvasively in rat using fluorinated glucose analogs, 2‐fluoro‐2‐deoxy‐D‐glucose (2‐FDG) or 3‐fluoro‐3‐deoxy‐D‐glucose (3‐FDG), and fluorine‐19 ( 19 F) nuclear magnetic resonance (NMR) imaging. I 9F images of 2‐FDG‐6‐phosphate, a main metabolite of 2‐FDG in the glycolytic pathway, showed high glucose utilization in the brain, spinal cord, and heart. Images of 3‐fluoro‐3‐deoxy‐D‐sorbitol (3‐FDSL), a main metabolite of 3‐FDG in the ARS pathway, demonstrated the heterogeneous nature of the spatial distribution of aldose reductase activities, being highest in the brain and lens. The extremely low toxicity of 3‐FDG indicates promise for clinical application of 3‐FDG NMR imaging. © 1988 Academic Press, Inc.